Study of BKM120 in Advanced Squamous Cell Carcinoma of Head and Neck
Status:
Unknown status
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
This study is to evaluate disease control rate (DCR) at 8 weeks of BKM120 administered as
therapy for patient with recurrent/metastatic head and neck squamous cell carcinoma.